From: Involvement of abnormal dystroglycan expression and matriglycan levels in cancer pathogenesis
Alteration | Levels | Tumor type | Cell line | References |
---|---|---|---|---|
DAG1 mRNA | Underexpressed | Acute promyelocytic leukemia (APL) | HL-60 | |
Acute myeloid leukemia (AML) | Kasumi-1 | [77] | ||
α-DG (core) protein | Underexpressed | Glioblastoma | U87MG | [66] |
A172MG | ||||
APL | HL-60 | |||
AML | Kasumi-1 | [77] | ||
α-DG glycosylation | Hypoglycosylated/unglycosylated | Oral squamous cells | SCC-4 | |
SCC9-, -15, -25 | [79] | |||
CAL27 | [81] | |||
Esophagus | FLO-1 | [82] | ||
Pancreas | PANC-1 | [87] | ||
BxPC-3 | ||||
Colon | HT29 | [100] | ||
LoVo | [104] | |||
Prostate | PC3 | |||
PC3-L | [105] | |||
TEM4-18 | ||||
LNCaP | ||||
DU145 | ||||
Cervix | HeLa | [69] | ||
Kidney | A498 | [103] | ||
Breast | MCF7 | |||
T4-2 | [67] | |||
BT549 | ||||
MDA-MB-231, −435, −453, −468 | ||||
MDA-MB-134VI, -436 | [106] | |||
CAMA1 | ||||
LY2 | ||||
HCC38, 70, 1143, 1419, 1500, 1937, 1954 | ||||
HS578T | ||||
AU565 | ||||
SUM52PE, 149PT, 159PT | ||||
ZR75B | ||||
Glioblastoma | U87MG | |||
U251MG | [106] | |||
A172MG | [66] | |||
LN-18 | ||||
LN-229 | [106] | |||
APL | HL-60 | |||
AML | Kasumi-1 | [77] | ||
Melanoma, skin | BLM | [108] | ||
M14 | ||||
IF6 | ||||
Rhabdomyosarcoma | PCB82, 232, 380 | [96] | ||
Rh18 | ||||
Lung | H1299 | [69] | ||
H2030 | ||||
β-DG protein | Underexpressed | Esophagus | FLO-1 | [82] |
Colon | HCT116 | |||
SW620 | ||||
Prostate | DU145 | |||
Breast | MCF7 | |||
T4-2 | [67] | |||
MDA-MB-134VI | [106] | |||
CAMA1 | ||||
LY2 | ||||
HCC1419, 1500, 1569, 1954 | ||||
BT474 | ||||
APL | HL-60 | |||
AML | Kasumi-1 | [77] | ||
Overexpressed | Breast | MCF7 | [110] | |
MDA-MB-453 | ||||
Melanoma, skin | IF6 | [108] |